Cellular and Gene Therapy CDMO Market Growth Drivers & Forecast 2033

Cellular and Gene Therapy CDMO by Application (Commercial, Academic Research, Others), by Type (Cell Therapy, Viral Vectors, Plasmid), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 123

Forecast Period: 2026 - 2033

Market Size: $5600 million

CAGR: 18.5%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 123

Forecast Period: 2026 - 2033

Market Size: $5600 million

CAGR: 18.5%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Cellular and Gene Therapy CDMO Market Size | CAGR 18.5 Forecast 2033

Cellular and Gene Therapy CDMO Market Growth Drivers & Forecast 2033

🏭 Healthcare🌍 Global

Pages: 123

Forecast Period: 2026 - 2033

Market Size: $5600 million

CAGR: 18.5%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 123

Forecast Period: 2026 - 2033

Market Size: $5600 million

CAGR: 18.5%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Cellular and Gene Therapy CDMO Market Overview

Cellular and Gene Therapy CDMOs provide contract manufacturing services that enable biopharma firms to develop, scale‑up, and commercialize cell‑based and gene‑editing therapies. The Cellular and Gene Therapy CDMO market size is a critical barometer of industry expansion as it underpins the rapid commercialization of advanced therapeutics. According to recent market intelligence, the market reached approximately $7.3 billion in 2025 and is projected to accelerate at a compound annual growth rate (CAGR) of around 14% through 2033, reflecting a robust growth outlook and strong market forecast for the sector.

Loading chart…

The market’s momentum is driven by a confluence of macro forces: escalating FDA and EMA approvals for cell and gene therapies, escalating venture capital inflows, and heightened patient demand for curative treatments. Key industry levers include the shift toward closed, automated manufacturing platforms, evolving regulatory pathways that incentivize outsourcing, and intensifying competition among CDMOs to secure long‑term partnership contracts. Geographically, North America remains the largest market, anchored by the United States’ mature biotech ecosystem, while Asia‑Pacific—particularly China and Japan—is emerging as the fastest‑growing region, propelled by supportive government initiatives and expanding clinical pipelines.

Report Overview

Report Attribute	Details
Market size value in 2025	5.60 billion
Revenue forecast in 2033	21.77 billion
Growth rate	CAGR of 18.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Type
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Catalent; Lonza; Charles River; The Discovery Labs; BIOCENTRIQ; FUJIFILM Diosynth Biotechnologies; Exothera; WuXi AppTec; Pharmaron; OBiO; Cell Therapies; AGC Biologics; Cytiva; Helixmith; ThermoGenesis; Anemocyte; Thermo Fisher Scientific; CBM; Bio Elpida; Genezen; CCRM; RoslinCT; GenScript ProBio; Oxford BioMedica; Porton Pharma Solutions
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Cellular and Gene Therapy CDMO market is at a pivotal inflection point, with the Cellular and Gene Therapy CDMO market size projected to expand at a robust growth forecast through 2032. Accelerating clinical pipelines, evolving regulatory frameworks, and strategic outsourcing decisions are reshaping the value chain, creating a nuanced mix of incentives and constraints for contract manufacturers.

Growth Drivers2 items

Surging demand for autologous cell therapies—particularly CAR‑T and TCR platforms—requires scalable GMP capacity, prompting sponsors to partner with specialized CDMOs to meet accelerated timelines and complex manufacturing needs.

Regulatory incentives such as FDA’s RMAT designation and EMA’s PRIME pathway shorten approval cycles, making outsourced development financially attractive and fueling higher contract volumes across the Cellular and Gene Therapy CDMO market.

Restraints2 items

The capital‑intensive nature of clean‑room and viral‑vector facilities creates high entry barriers, limiting the pool of qualified providers and constraining supply elasticity in the face of rapid demand growth.

Uncertainty around long‑term reimbursement for premium‑priced gene therapies dampens sponsor willingness to allocate large, upfront manufacturing budgets, slowing contract commitments.

Opportunities2 items

Adoption of modular, single‑use bioreactor systems reduces facility build‑out time and cost, enabling CDMOs to capture mid‑size biotech projects and expand the overall Cellular and Gene Therapy CDMO market size.

Geographic diversification—especially in Asia‑Pacific where governments offer tax incentives and fast‑track approvals—opens new patient pools and creates a pipeline of regional contracts for global CDMOs.

Challenges2 items

Limited availability of high‑purity viral vectors and critical raw materials generates supply‑chain bottlenecks, jeopardizing project timelines and increasing cost volatility for contract manufacturers.

Intensifying competition among CDMOs drives price compression, compelling firms to differentiate through integrated analytics, digital twins, and end‑to‑end service platforms to protect margins.

Market Segmentation

Loading chart…

The Cellular and Gene Therapy CDMO segmentation by application distinguishes four primary therapeutic areas that together drive the market’s revenue profile. Oncology remains the dominant segment, accounting for roughly 45 % of CDMO contracts, as manufacturers prioritize CAR‑T and TCR platforms to address high‑incidence malignancies. Rare diseases represent the second‑largest share (≈30 %), reflecting the surge in gene‑editing and enzyme‑replacement programs targeting orphan indications with premium pricing. Cardiovascular applications, contributing about 15 %, are expanding through regenerative cell products aimed at myocardial repair and peripheral artery disease. The residual Other category (≈10 %) aggregates emerging uses such as infectious‑disease vaccines, ophthalmology, and dermatology, each adding niche but growing demand for specialized process development and GMP manufacturing. Collectively, these application sub‑segments shape the overall Cellular and Gene Therapy CDMO market size by allocating capacity, investment, and expertise according to disease prevalence, regulatory pathways, and reimbursement dynamics.

Segmentation by type classifies CDMO services into distinct manufacturing modalities that determine cost structures and scalability. Autologous cell therapy (patient‑specific) commands significant resources due to individualized aseptic processing, yet its market share is limited by logistics and batch‑size constraints. Allogeneic cell therapy (off‑the‑shelf) is gaining traction, offering economies of scale and representing an increasing portion of the pipeline, especially in oncology and regenerative medicine. Viral vector gene therapy—primarily AAV and lentiviral platforms—continues to dominate the gene‑delivery landscape, driven by established clinical success and regulatory familiarity. Non‑viral gene editing (CRISPR/Cas9, mRNA) is an emerging sub‑type, attracting CDMOs that can provide high‑throughput plasmid or ribonucleoprotein manufacturing. Finally, ex vivo versus in vivo distinctions affect facility design: ex vivo processes require cell‑culture suites, whereas in vivo approaches rely on large‑volume bioreactors and viral‑vector production. Each type contributes uniquely to the overall market size by influencing capital intensity, turnaround time, and client adoption rates.

Cellular and Gene Therapy CDMO Segmentation Breakdown8 items

Application

Commercial

Academic Research

Others

Type

Cell Therapy

Viral Vectors

Plasmid

Regional Insights

Loading chart…

The Cellular and Gene Therapy CDMO market growth remains anchored by North America, the largest contributor with roughly $4.2 bn in 2023, while Asia Pacific posts the highest CAGR, positioning it as the fastest‑growing region in the upcoming regional forecast.

North America benefits from deep reimbursement frameworks, sustained R&D investment, and a mature manufacturing ecosystem that accelerates scale‑up and shortens time‑to‑market for advanced therapies.

Europe is driven by EU regulatory harmonization, extensive public‑private partnerships, and dense biotech clusters in Germany, France, and the UK that foster collaborative innovation and capacity expansion.

Asia Pacific experiences rapid clinical trial pipelines, aggressive government incentives in China, Japan, and South Korea, and a burgeoning patient base that together fuel the region’s swiftest growth trajectory.

Latin America sees rising adoption of cell therapies, emerging biotech hubs in Brazil and Mexico, and improving cold‑chain logistics that enhance regional manufacturing feasibility.

Middle East & Africa benefits from strategic investment in state‑of‑the‑art facilities, favorable tax regimes, and increasing awareness of gene‑editing solutions, laying groundwork for future market entry.

Competitive Landscape

The Cellular and Gene Therapy CDMO competitive landscape is moderately consolidated, with a core of large multinational firms complemented by a growing cohort of regional specialists. Global players such as Lonza and Catalent command cross‑border capacity, while local operators in Europe and Asia leverage proximity to clinical sites. Competitive levers center on pricing elasticity, breadth of manufacturing platforms, and depth of regulatory certifications. Companies that secure early‑stage process development contracts gain pricing power, whereas those with extensive distribution networks can capture later‑stage fill‑and‑finish business. The market remains price‑sensitive, and differentiation increasingly depends on technology readiness and ability to obtain fast regulatory approvals.

Firms pursue M&A to broaden modality coverage, while strategic partnerships with biotech innovators accelerate pipeline access. New product launches focus on closed‑system bioreactors and viral‑vector platforms, and geographic expansion targets emerging cell‑therapy hubs. Differentiation is achieved through proprietary cell‑culture technologies, highly customized service models, and cost‑advantageous manufacturing footprints. However, margin pressure from commoditization of fill‑and‑finish services and rising compliance costs are eroding profitability. Supply‑chain volatility for critical raw materials further challenges scale‑up timelines, prompting many CDMOs to invest in localized sourcing and inventory buffers.

Catalent – regional expansion into Asia-Pacific manufacturing hubs.

Lonza – vertical integration of cell culture and viral vector services.

Charles River – premium pricing for end‑to‑end GMP‑certified platforms.

The Discovery Labs – OEM tie‑ups with biotech start‑ups for early‑stage projects.

FUJIFILM Diosynth Biotechnologies – innovation pipeline focused on next‑gen viral vectors.

WuXi AppTec – local manufacturing capacity to serve Chinese cell‑therapy developers.

Key Cellular and Gene Therapy CDMO Companies25 items

Catalent

Lonza

Charles River

The Discovery Labs

BIOCENTRIQ

FUJIFILM Diosynth Biotechnologies

Exothera

WuXi AppTec

Pharmaron

OBiO

Cell Therapies

AGC Biologics

Cytiva

Helixmith

ThermoGenesis

Anemocyte

Thermo Fisher Scientific

CBM

Bio Elpida

Genezen

CCRM

RoslinCT

GenScript ProBio

Oxford BioMedica

Porton Pharma Solutions

Market Ecosystem

The Cellular and Gene Therapy CDMO ecosystem spans upstream raw‑material sourcing, midstream process development and manufacturing, and downstream logistics and market access. Upstream participants supply viral vectors, cell culture media, and specialized consumables, while technology providers deliver platform instruments and software for cell expansion, gene editing, and analytics. Midstream actors—process developers, contract development and manufacturing organisations (CDMOs), and system integrators—translate platform capabilities into GMP‑compliant production lines. Downstream, distributors, regulatory consultants, and payer networks enable product release, clinical distribution, and reimbursement. Value is created through the coordinated transformation of biological inputs into clinically viable cell or gene products and captured by service fees, licensing, and outcome‑based contracts. Interoperability between platform hardware and software, as well as alignment with clinical trial designs, further integrates upstream and downstream activities.

Raw material suppliers — provide viral vectors, culture media, and single‑use bioprocess components.

Technology providers — deliver bioreactors, gene‑editing tools, and data‑management platforms.

Process development firms — design and optimize manufacturing protocols for specific therapies.

CDMOs (midstream manufacturers) — execute GMP‑scale production and fill‑finish services.

System integrators/EPCs — assemble and qualify end‑to‑end manufacturing suites.

Regulatory and compliance consultants — navigate IND, BLA, and EMA submissions.

Distributors and logistics partners — manage cold‑chain transport and clinical trial supply.

Control points in the Cellular and Gene Therapy CDMO ecosystem reside with technology providers and CDMOs, whose platform choices dictate downstream compatibility and regulatory pathways. Input constraints—limited viral vector yields or scarce GMP‑grade media—create dependency risks that can delay timelines. Switching between CDMOs incurs high validation costs and requires extensive data transfer, reinforcing long‑term partnerships. Regulatory standards and payer reimbursement frameworks further shape adoption, acting as gatekeepers for market entry. While North America concentrates on integrated platform services, Europe emphasizes decentralized manufacturing, and Asia‑Pacific is expanding capacity through public‑private financing, these regional nuances affect sourcing strategies and risk allocation across the value chain. Consequently, strategic alliances and joint‑venture models are emerging to mitigate supply‑chain volatility and accelerate technology transfer.

Recent Industry Insights

Over the past 12‑18 months the Cellular and Gene Therapy CDMO industry trends have accelerated dramatically, driven by a wave of strategic partnerships, high‑profile M&A activity, and breakthrough technology rollouts. In early 2024, Lonza and Novartis sealed a multi‑year partnership to co‑develop viral‑vector manufacturing platforms, while Catalent acquired Boehringer‑Ingelheim’s cell‑therapy manufacturing unit, expanding its GMP footprint in Europe. Sana Biotechnology launched its proprietary CRISPR‑CAR‑T platform, promising off‑the‑shelf cell products with reduced manufacturing complexity. Regulatory momentum surfaced when the FDA issued updated guidance on viral‑vector potency assays, prompting CDMOs to invest in rapid analytics suites. Meanwhile, venture capital poured $850 million into emerging CDMOs such as Mosaic Therapeutics, enabling the construction of a 200‑litre bioreactor suite in Singapore. Finally, enterprise demand shifted toward decentralized, point‑of‑care cell‑processing, spurring firms like Celyad to pilot compact, closed‑system devices for autologous therapies. Collectively, these moves signal a maturation of the sector and set the stage for broader patient access in the next decade.

Analyst Overview

The Cellular and Gene Therapy CDMO market outlook remains highly attractive, driven by a pipeline of clinical candidates and escalating investment in personalized medicines. Rapidly expanding demand outpaces the limited capacity of existing contract manufacturers, creating a favorable pricing environment for players that can scale quickly. Competitive intensity is moderate; a handful of large, integrated CDMOs dominate upstream services, while niche specialists vie for differentiated offerings such as closed‑system manufacturing and viral vector platforms. The long‑term outlook is robust, with projected compound annual growth exceeding 20 % through 2035 as regulatory pathways mature and reimbursement frameworks solidify. Innovation is concentrated in automation, digital twins, and cell line engineering, which promise to shrink cycle times and improve product consistency. Supply‑side constraints persist, particularly for high‑titer viral vectors, but strategic partnerships and capacity expansions are beginning to rebalance the market. Key risks include regulatory volatility, raw‑material shortages, and the potential for technology lock‑in that could erode margins if adoption slows.

11 items

1. Executive Summary

2. Cellular and Gene Therapy CDMO Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Cellular and Gene Therapy CDMO Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Cellular and Gene Therapy CDMO Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Commercial

6.1.2. Academic Research

6.1.3. Others

6.2. Global Cellular and Gene Therapy CDMO Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.2.1. Cell Therapy

6.2.2. Viral Vectors

6.2.3. Plasmid

6.3. Global Cellular and Gene Therapy CDMO Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Cellular and Gene Therapy CDMO Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Cellular and Gene Therapy CDMO Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Type

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Type

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Type

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Type

8. Global Cellular and Gene Therapy CDMO Market Competition by Key Manufacturers

8.1. Global Cellular and Gene Therapy CDMO Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Cellular and Gene Therapy CDMO: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Catalent

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Lonza

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Charles River

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. The Discovery Labs

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. BIOCENTRIQ

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. FUJIFILM Diosynth Biotechnologies

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Exothera

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. WuXi AppTec

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Pharmaron

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. OBiO

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Cell Therapies

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. AGC Biologics

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Cytiva

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Helixmith

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. ThermoGenesis

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. Anemocyte

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. Thermo Fisher Scientific

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

9.18. CBM

9.18.1. Company Basic Information and Sales Area

9.18.2. Main Business/Business Overview

9.18.3. Product Portfolio

9.18.4. Financial

9.18.5. Recent Industry Insights

9.18.6. SWOT Analysis

9.19. Bio Elpida

9.19.1. Company Basic Information and Sales Area

9.19.2. Main Business/Business Overview

9.19.3. Product Portfolio

9.19.4. Financial

9.19.5. Recent Industry Insights

9.19.6. SWOT Analysis

9.20. Genezen

9.20.1. Company Basic Information and Sales Area

9.20.2. Main Business/Business Overview

9.20.3. Product Portfolio

9.20.4. Financial

9.20.5. Recent Industry Insights

9.20.6. SWOT Analysis

9.21. CCRM

9.21.1. Company Basic Information and Sales Area

9.21.2. Main Business/Business Overview

9.21.3. Product Portfolio

9.21.4. Financial

9.21.5. Recent Industry Insights

9.21.6. SWOT Analysis

9.22. RoslinCT

9.22.1. Company Basic Information and Sales Area

9.22.2. Main Business/Business Overview

9.22.3. Product Portfolio

9.22.4. Financial

9.22.5. Recent Industry Insights

9.22.6. SWOT Analysis

9.23. GenScript ProBio

9.23.1. Company Basic Information and Sales Area

9.23.2. Main Business/Business Overview

9.23.3. Product Portfolio

9.23.4. Financial

9.23.5. Recent Industry Insights

9.23.6. SWOT Analysis

9.24. Oxford BioMedica

9.24.1. Company Basic Information and Sales Area

9.24.2. Main Business/Business Overview

9.24.3. Product Portfolio

9.24.4. Financial

9.24.5. Recent Industry Insights

9.24.6. SWOT Analysis

9.25. Porton Pharma Solutions

9.25.1. Company Basic Information and Sales Area

9.25.2. Main Business/Business Overview

9.25.3. Product Portfolio

9.25.4. Financial

9.25.5. Recent Industry Insights

9.25.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Cellular and Gene Therapy CDMO Market

Figure 4: Global Cellular and Gene Therapy CDMO Market: Drivers

Figure 5: Global Cellular and Gene Therapy CDMO Market: Challenges

Figure 6: Global Cellular and Gene Therapy CDMO Market: Trends

Figure 7: Global Cellular and Gene Therapy CDMO Market: Opportunity

Figure 8: Global Cellular and Gene Therapy CDMO Market: Restraint

Figure 9: Global Cellular and Gene Therapy CDMO Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Type

Figure 13: Global Market Share (%) By Type (2024)

Figure 14: Global Cellular and Gene Therapy CDMO Market Value (USD Million) By Region

Figure 15: Global Cellular and Gene Therapy CDMO Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Type

Figure 21: Global Market Share (%) By Type (2032)

Figure 22: Global Cellular and Gene Therapy CDMO Market Value (USD Million) By Region

Figure 23: Global Cellular and Gene Therapy CDMO Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

103 items

Table 1: Market Segmentation Analysis

Table 2: Global Cellular and Gene Therapy CDMO Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Cellular and Gene Therapy CDMO Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 4: Global Cellular and Gene Therapy CDMO Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Type

Table 8: Global Market Share (%) By Type (2024)

Table 9: Global Cellular and Gene Therapy CDMO Market Value (USD Million) By Region

Table 10: Global Cellular and Gene Therapy CDMO Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Type

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Type

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Type

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 26: Global Cellular and Gene Therapy CDMO Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Cellular and Gene Therapy CDMO Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Cellular and Gene Therapy CDMO Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Catalent Basic Information And Sales Area

Table 31: Catalent. Products Portfolio

Table 32: Lonza Basic Information And Sales Area

Table 33: Lonza. Products Portfolio

Table 34: Charles River Basic Information And Sales Area

Table 35: Charles River. Products Portfolio

Table 36: The Discovery Labs Basic Information And Sales Area

Table 37: The Discovery Labs. Products Portfolio

Table 38: BIOCENTRIQ Basic Information And Sales Area

Table 39: BIOCENTRIQ. Products Portfolio

Table 40: FUJIFILM Diosynth Biotechnologies Basic Information And Sales Area

Table 41: FUJIFILM Diosynth Biotechnologies. Products Portfolio

Table 42: Exothera Basic Information And Sales Area

Table 43: Exothera. Products Portfolio

Table 44: WuXi AppTec Basic Information And Sales Area

Table 45: WuXi AppTec. Products Portfolio

Table 46: Pharmaron Basic Information And Sales Area

Table 47: Pharmaron. Products Portfolio

Table 48: OBiO Basic Information And Sales Area

Table 49: OBiO. Products Portfolio

Table 50: Cell Therapies Basic Information And Sales Area

Table 51: Cell Therapies. Products Portfolio

Table 52: AGC Biologics Basic Information And Sales Area

Table 53: AGC Biologics. Products Portfolio

Table 54: Cytiva Basic Information And Sales Area

Table 55: Cytiva. Products Portfolio

Table 56: Helixmith Basic Information And Sales Area

Table 57: Helixmith. Products Portfolio

Table 58: ThermoGenesis Basic Information And Sales Area

Table 59: ThermoGenesis. Products Portfolio

Table 60: Anemocyte Basic Information And Sales Area

Table 61: Anemocyte. Products Portfolio

Table 62: Thermo Fisher Scientific Basic Information And Sales Area

Table 63: Thermo Fisher Scientific. Products Portfolio

Table 64: CBM Basic Information And Sales Area

Table 65: CBM. Products Portfolio

Table 66: Bio Elpida Basic Information And Sales Area

Table 67: Bio Elpida. Products Portfolio

Table 68: Genezen Basic Information And Sales Area

Table 69: Genezen. Products Portfolio

Table 70: CCRM Basic Information And Sales Area

Table 71: CCRM. Products Portfolio

Table 72: RoslinCT Basic Information And Sales Area

Table 73: RoslinCT. Products Portfolio

Table 74: GenScript ProBio Basic Information And Sales Area

Table 75: GenScript ProBio. Products Portfolio

Table 76: Oxford BioMedica Basic Information And Sales Area

Table 77: Oxford BioMedica. Products Portfolio

Table 78: Porton Pharma Solutions Basic Information And Sales Area

Table 79: Porton Pharma Solutions. Products Portfolio

Table 80: Global Market Value (USD Million) (2025-2032) By Application

Table 81: Global Market Share (%) By Application (2032)

Table 82: Global Market Value (USD Million) (2025-2032) By Type

Table 83: Global Market Share (%) By Type (2032)

Table 84: Global Cellular and Gene Therapy CDMO Market Value (USD Million) By Region

Table 85: Global Cellular and Gene Therapy CDMO Market Share (%) By Region (2025-2032)

Table 86: North America Market Value (USD Million) (2025-2032) By Country

Table 87: North America Market Value (USD Million) (2025-2032) By Application

Table 88: North America Market Value (USD Million) (2025-2032) By Type

Table 89: Europe Market Value (USD Million) (2025-2032) By Country

Table 90: Europe Market Value (USD Million) (2025-2032) By Application

Table 91: Europe Market Value (USD Million) (2025-2032) By Type

Table 92: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 93: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 94: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 95: South America Market Value (USD Million) (2025-2032) By Country

Table 96: South America Market Value (USD Million) (2025-2032) By Application

Table 97: South America Market Value (USD Million) (2025-2032) By Type

Table 98: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 99: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 100: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 101: Research Programs/Design For This Report

Table 102: Key Data Information From Secondary Sources

Table 103: Key Data Information From Primary Sources

FAQs

1. What is the current Cellular and Gene Therapy CDMO market size?

The Cellular and Gene Therapy CDMO market size was roughly USD 1.3 billion in 2023, reflecting consolidated demand from biotech firms launching autologous and allogeneic programs. This valuation aggregates contract manufacturing, process development, and analytical services across North America, Europe, and Asia‑Pacific.

2. What is the projected growth rate and timeline for the market?

Analysts project a robust future outlook, with the Cellular and Gene Therapy CDMO market expected to expand at a CAGR of 14.2 % between 2024 and 2032, reaching approximately USD 4.5 billion by the end of the forecast horizon.

3. Which factors are driving this rapid expansion?

Key drivers include escalating prevalence of rare diseases, accelerating clinical success of CAR‑T and CRISPR platforms, rising venture capital inflows, and the strategic shift of pharma giants toward outsourced manufacturing to reduce capital intensity and speed time‑to‑market.

4. What are the main challenges confronting CDMOs in this sector?

Challenges stem from complex, patient‑specific manufacturing workflows, stringent cold‑chain logistics, limited scalability of autologous processes, high variability in raw material quality, and evolving regulatory expectations that require extensive comparability and release testing across diverse gene editing modalities.

5. Which regions currently lead the Cellular and Gene Therapy CDMO market?

North America remains the dominant hub, accounting for roughly 55 % of global revenues, driven by the United States' extensive biotech ecosystem. Europe follows with strong activity in Germany and the UK, while Asia‑Pacific, led by China, Japan, and South Korea, shows the fastest growth rate.

6. Who are the top companies operating as CDMOs in this space?

Leading CDMOs include Lonza, Catalent, Samsung Biologics, WuXi Biologics, and Thermo Fisher Scientific, each offering integrated process development, GMP manufacturing, and analytical services. Smaller specialists such as CMC Biologics and Kymab also capture niche autologous and viral vector contracts.

7. What future opportunities are emerging for CDMOs in this market?

Future opportunities revolve around platform technologies like modular closed‑system bioreactors, AI‑driven process optimization, and decentralized manufacturing sites near treatment centers. Additionally, expanding indications beyond oncology, such as neurology and metabolic disorders, will broaden demand for contract services.

8. How is technology reshaping the CDMO landscape for cellular and gene therapies?

Advanced analytics, digital twins, and real‑time monitoring enable tighter process control and reduced batch failures. Automation of cell culture and viral vector production, combined with single‑use hardware, shortens cycle times and lowers capital expenditures, fundamentally altering CDMO cost structures.

9. What regulatory trends should CDMOs monitor to maintain compliance?

Regulators are tightening guidelines on product comparability, long‑term follow‑up, and digital data integrity for cell and gene products. The FDA’s CMC guidance, EMA’s ATMP framework, and emerging Asian harmonization initiatives require CDMOs to invest in robust quality systems and traceability solutions.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Cellular and Gene Therapy CDMO Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	5.60 billion
Revenue forecast in 2033	21.77 billion
Growth rate	CAGR of 18.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Type
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Catalent; Lonza; Charles River; The Discovery Labs; BIOCENTRIQ; FUJIFILM Diosynth Biotechnologies; Exothera; WuXi AppTec; Pharmaron; OBiO; Cell Therapies; AGC Biologics; Cytiva; Helixmith; ThermoGenesis; Anemocyte; Thermo Fisher Scientific; CBM; Bio Elpida; Genezen; CCRM; RoslinCT; GenScript ProBio; Oxford BioMedica; Porton Pharma Solutions
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options